Ultragenyx Pharm Stock Price, News & Analysis

Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of 44,805 restricted stock units (RSUs) to 20 newly hired non-executive officers. The compensation committee approved these awards under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2025. The RSUs were granted as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4). The vesting schedule spans four years, with 25% of shares vesting annually on the grant date anniversary, contingent on continuous employment.

Ultragenyx Pharmaceutical (NASDAQ: RARE) has released its 2024 Impact Report, highlighting the company's commitment to rare disease innovation and corporate responsibility. The report is structured around six key pillars: Innovation, Patients, People, Communities, Planet, and Governance. Key achievements include: successful transfer of DTX401 gene therapy manufacturing to their Bedford facility, supporting over 650 patients in 50 countries through access programs, maintaining 88% employee engagement, and approving $3M+ in charitable donations. The company advanced several clinical programs for rare diseases including osteogenesis imperfecta and Angelman syndrome. Ultragenyx received multiple recognitions in 2024, including being named among Barron's 100 Most Sustainable Companies and Top Places to Work in the USA. The company demonstrated environmental commitment by purchasing 100% renewable electricity for its headquarters and achieving My Green Lab Green certification.

Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in novel therapies for rare and ultra-rare genetic diseases, announced that CFO and Executive VP Howard Horn will participate in a fireside chat at Bank of America's 2025 Healthcare Conference. The event is scheduled for Tuesday, May 13, 2025, at 8:00 a.m. PT. Investors and interested parties can access both the live and archived webcast of the panel through Ultragenyx's investor relations website.

Ultragenyx Pharmaceutical (NASDAQ: RARE) reported Q1 2025 financial results with total revenue of $139 million, up 28% year-over-year. Key revenue drivers include Crysvita at $103 million (25% growth) and Dojolvi at $17 million. The company reported a net loss of $151 million ($1.57 per share), improved from $171 million loss in Q1 2024. Cash position stands at $563 million. Ultragenyx reaffirmed its 2025 guidance, expecting total revenue between $640-670 million. Notable pipeline progress includes UX111's BLA review for Sanfilippo syndrome with PDUFA date of August 18, 2025, and advancement of multiple Phase 3 programs including UX143 for osteogenesis imperfecta and GTX-102 for Angelman syndrome.

Ultragenyx Pharmaceutical (NASDAQ: RARE), a leading biopharmaceutical company specializing in rare and ultra-rare genetic diseases, has scheduled its first quarter 2025 financial results conference call.

The earnings call will take place on Tuesday, May 6, 2025, at 5:00 p.m. ET. During this call, the company will present its financial performance for the quarter ending March 31, 2025, along with a corporate update.

Investors and interested parties can access the live webcast through the company's investor relations website at https://ir.ultragenyx.com/events-presentations. A replay of the conference call will remain available for three months following the presentation.

Ultragenyx Pharmaceutical (NASDAQ: RARE) has announced the grant of 36,831 restricted stock units to 21 newly hired non-executive officers. The awards were approved by the company's compensation committee and issued under the Ultragenyx Employment Inducement Plan on April 16, 2025.

The stock units feature a four-year vesting schedule, with 25% of shares vesting annually on the grant date anniversary, contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement for new hires.

Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of 21,806 restricted stock units to 16 newly hired non-executive officers. The awards, approved by the compensation committee and granted under the Ultragenyx Employment Inducement Plan on March 16, 2025, serve as an employment inducement in compliance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units feature a four-year vesting schedule, with 25% of shares vesting annually on the grant date anniversary, contingent on continuous employment.

Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in novel therapies for rare and ultrarare genetic diseases, has announced its participation in three major investor conferences in March 2025.

The company's Chief Medical Officer, Dr. Eric Crombez, will represent Ultragenyx at:

• The 45th Annual Cowen Healthcare Conference in Boston on March 3
• The Barclays 27th Annual Global Healthcare Conference in Miami on March 11
• The Leerink Partners Global Biopharma Conference in Miami on March 12

At each event, Dr. Crombez will participate in a fireside chat and conduct one-on-one meetings. Investors can access live and archived webcasts of the fireside chats through Ultragenyx's investor relations website.

Ultragenyx Pharmaceutical (NASDAQ: RARE) has announced the grant of 23,760 restricted stock units to 10 newly hired non-executive officers. The compensation committee approved these awards under the Ultragenyx Employment Inducement Plan, with a grant date of February 16, 2025. The grants, made in accordance with Nasdaq Listing Rule 5635(c)(4), serve as employment inducements for the new hires.

The restricted stock units have a four-year vesting schedule, with 25% of the shares vesting annually on the grant date anniversary, contingent on continuous employment.